<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280588</url>
  </required_header>
  <id_info>
    <org_study_id>MRCTA, ECFAH of FMU [2020]027</org_study_id>
    <nct_id>NCT04280588</nct_id>
  </id_info>
  <brief_title>Fingolimod in COVID-19</brief_title>
  <official_title>Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2
      pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane
      formation, timely and appropriate use of immune modulator together with ventilator support
      should be considered for the severe patients to prevent ARDS development. The
      sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology
      modulator which has been widely used in multiple sclerosis.The aim of this study was to
      determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 22, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of pneumonia severity on X-ray images</measure>
    <time_frame>5 day after fingolimod treatment</time_frame>
    <description>The lesion change on X-ray images from day 5 to baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronavirus Disease (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 0.5 mg</intervention_name>
    <description>Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who were diagnosed with the common type of NCP (including severe risk
             factors) and severe cases of new coronavirus pneumonia;

          -  Aged 18 to 85 years;

          -  Patients or authorized family members volunteered to participate in this study and
             signed informed consent.

        Exclusion Criteria:

          -  Patients with any history of bradyarrhythmia or atrioventricular blocks

          -  Patients who are participating in other drug clinical trials;

          -  Pregnant or lactating women;

          -  ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;

          -  Definite diagnosis of rheumatic immune-related diseases;

          -  Long-term oral anti-rejection or immunomodulatory drugs;

          -  Patients with active pulmonary tuberculosis, with definite bacterial and fungal
             infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Fu</last_name>
    <phone>+86</phone>
    <phone_ext>+86</phone_ext>
    <email>fuying1995@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wan-Jin Chen</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan-Jin Chen, MD</last_name>
      <phone>+1386061359</phone>
      <phone_ext>+1386061359</phone_ext>
      <email>wanjinchen75@fjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ning Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wan-Jin Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Ning Wang, MD., PhD.</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

